Table 3.

Matrix effect and recovery of RO4929097 and the internal standard D6-RO4929097 from 6 different sources of human plasma and from phosphate buffer solution (PBS, pH 7.2).

Matrix	Analyte	Nominal concentration (ng/ml)a	Mean peak area			Matrix effect (%)e	Recovery (%)f
			Set 1b	Set 2c	Set 3d
Human plasma
	RO4929097	15	1616	1818	1548	117 (2.5%)	89 (9.0%)
		800	73806	87629	87075	104 (3.0%)	84 (5.1%)
		1600	169103	214875	181157	119 (1.8%)	79 (3.7%)
	D6-RO4929097	100	10876	13812	11774	117 (3.3%)	79 (7.4%)
PBS
	RO4929097	1.5	765	973	1049	93 (7.6%)	79 (2.3%)
		80	35172	37314	36839	101 (0.8%)	94 (0.9%)
		160	70768	75336	75631	99 (0.5%)	94 (0.3%)
	D6-RO4929097	100	7244	7852	7835	99 (6.0%)	98 (7.1%)

^aThe nominal concentrations of the analyte spiked in plasma before extraction (set 1). The same amounts of the analyte as in set 1 were spiked in the mobile phase and in plasma or PBS extract for set 2 and set 3.

^bThe mean peak area of an analyte that was spiked before extraction in plasma from 6 different sources (donors), each source of plasma in triplicate measurements.

^cThe mean peak area of an analyte that was spiked postextraction in plasma extracts from 6 different sources of human plasma, each source of plasma in triplicate measurements.

^dThe mean peak area of an analyte that was spiked in the mobile phase from triplicate measurements.

^eMatrix effect is expressed as the ratio of the mean peak area of an analyte spiked postextraction (set 2) to the mean peak area of the same amount of analyte spiked in the mobile phase (set 3). Data are shown as the mean (%CV) from six different sources of plasma.

^fExtraction recovery is calculated as the ratio of the mean peak area of an analyte spiked before extraction (set 1) to the mean peak area of the same amount of the analyte spiked postextraction (set 2). Data are shown as the mean (%CV) from six different source of plasma.